Form 4: Pfizer Director Cyrus Taraporevala Reports Acquisition of Phantom Stock Units

Director Cyrus Taraporevala reports acquiring phantom stock units in Pfizer Inc. through deferred compensation.

Summary

• Cyrus Taraporevala, a director of Pfizer Inc., filed a Form 4 with the SEC.
• The filing reports the acquisition of phantom stock units on June 27, 2024, and June 28, 2024.
• On June 27, 2024, 6,101.311 phantom stock units were acquired at a price of $27.8.
• On June 28, 2024, an additional 58.912 phantom stock units were acquired at a price of $27.98.
• These units are part of the Nonfunded Deferred Compensation and Unit Award Plan for Non-Employee Directors.
• The units represent deferred director's compensation and will be settled in cash or common stock upon retirement from the Board of Directors.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive as it reflects standard director compensation practices and aligns director interests with company performance.

Positives

• The acquisition of phantom stock units aligns the director's interests with the long-term performance of the company.
• The deferred compensation plan is a common practice for non-employee directors.

Future Outlook

The phantom stock units will be settled in cash or common stock upon the director's retirement, linking their compensation to the company's future performance.

Industry Context

Deferred compensation plans, including phantom stock units, are a common way for companies to compensate non-employee directors, aligning their interests with those of shareholders.

Stakeholder Impact

• The acquisition of phantom stock units by a director can positively influence shareholder confidence by aligning management's interests with the company's long-term success.

Key Dates